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have demonstrated nefopam to be very effective in the
prevention of postoperative shivering in patients after
general anesthesia (Rosa et al., 1995) without affecting
the recovering time between the end of anesthesia and
extubation (Piper et al., 1999). Unpleasant adverse
effects during therapeutic use have been also reported
including dizziness, headache, nausea, vomiting and
sweating, consistent with a central mode of action of
the drug. Although these side effects are usually minor
and not very long lasting, they can probably explain
the limited development of nefopam for post-
operative use in the last years.
The analgesic properties of nefopam are now being
reinvestigated. This drug has been recently demon-
strated to induce a rapid and strong depression of the
nociceptive flexion (RIII) reflex in humans (Guirimand
et al., 1999), probably through a central mechanism of
action (Hunskaar et al., 1987; Fasmer et al., 1987).
However, the detailed mechanisms underlying the
pharmacological actions of nefopam remain unclear.
Evidence exist suggesting a possible action of nefopam
on the neurotransmission mediated by glutamate.
Thus, nefopam is a cyclic analogue of orphenadrine
and diphenhydramine, drugs originally synthesized
as central myorelaxants which exert unspecific antag-
onistic activity at the phencyclidine binding site of
NMDA receptors (Kornhuber et al., 1995). Further-
more, nefopam shows pre-emptive analgesic effects in
a model of neuropathy (chronic constriction injury of
Summary. Nefopam hyghochloride is a potent analgesic compound
commercialized in most Western Europe for 20 years, which pos-
sesses a profile distinct from that of opioids or anti-inflammatory
drugs. Previous evidence suggested a central action of nefopam
but the detailed mechanisms remain unclear. While, nefopam struc-
ture resembles that of orphenadrine, an uncompetitive NMDA
receptor antagonist, here we report that differently from
orphenadrine, nefopam (100 µM) failed to protect cultured cerebel-
lar neurons from excitotoxicity following direct exposure of neurons
to glutamate. Moreover, nefopam failed to displace MK-801 bind-
ing to hippocampal membranes. Nefopam effectively prevented
NMDA receptor-mediated early appearance (30 min) of toxicity
signs induced by the voltage sensitive sodium channel (VSSC)
activator veratridine. The later phase (24 h) of neurotoxicity
by veratridine occurring independently from NMDA receptor
activation, was also prevented by nefopam. Nefopam effect was not
mimicked by the GABA receptor agonist muscimol.
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Introduction
Nefopam hydrochloride is a potent analgesic com-
pound commercialized in most Western Europe for
20 years. Nefopam possesses a profile distinct from
that of opioids or anti-inflammatory drugs. It does
not cause tolerance, withdrawal reactions or physical
dependence, and the potential for its abuse is very
low (Heel et al., 1980). Furthermore, nefopam does
not produce respiratory depression even in the
post-operative period (Gasser and Bellville, 1975;
Gerbershagen and Schaffner, 1979). Clinical studies
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the sciatic nerve) (Biella et al., 2002) which involves
the activation of NMDA receptors.
In this study we tested nefopam for protection
against NMDA-receptor mediated neurotoxicity in
cultured cerebellar neurons, as well as for affinity to
the phencyclidine binding site of the NMDA receptor
in rat hippocampal membranes.
Materials and methods
Cell cultures
Primary cultures of rat cerebellar neurons were prepared as previ-
ously described (Novelli et al., 1988; 1992). Briefly, cerebella from 8-
day-old pups were dissected, cells were dissociated and suspended in
basal Eagle’s medium with 25 mM KCl, 2 mM glutamine, 100 µg/ml
gentamycin and 10% fetal calf serum. Cells were seeded in poly-
L-Lysine coated (5 µg/ml) 35 mm dishes at 2.5  105 cells/cm2 and
incubated at 37°C in a 5% CO2, 95% humidity, atmosphere. Cyto-
sine arabinoside (10 µM) was added after 20–24 h of culture to
inhibit the replication of non-neuronal cells. After 8 days in vitro,
morphologically identifiable granule cells accounted for more than
95% of the neuronal population, the remaining 5% being essentially
GABAergic neurons. Astrocytes did not exceed 3% of the overall
number of cells in culture. Cerebellar neurons were kept alive for
more than 40 days in culture by replenishing the growth medium
with glucose every 4 days and compensating for lost amounts of
water, due to evaporation.
Neurotoxicology
Neurons were used between 14–20 days in culture. Drugs were
added into the growth medium at the indicated concentrations, and
neuronal cultures were observed for signs of early neurotoxicity at
30 min., as well as for neuronal survival 24 h thereafter, by phase
contrast microscopy. To quantify neuronal survival cultures were
stained with fluorescein diacetate and ethidium bromide (Novelli et
al., 1988; Fernández et al., 1991), photographs of three randomly
selected culture fields were taken and live and dead neurons were
counted. Results were expressed as percentage of live neurons Total
number of neurons per dish was calculated considering the ratio
between the area of the dish and the area of the picture (3,000).
Receptor binding
Male Sprague-Dawley rats (200–250 g) were decapitated and their
brains were removed rapidly. Hippocampi were dissected and
pooled. Tissue preparation was performed according to the method
of Wong and collaborators (Wong et al., 1986) with minor modifica-
tion. In brief, hippocampi were homogenized in 9 volumes of ice-
cold 0.32 M sucrose by nine strokes with a Teflon/glass homogenizer
at 500 rpm. The homogenate was centrifuged at 1,000  g, and the
supernatant was recentrifuged at 10,000  g for 20 min at 4°C. The
pellet was suspended in assay buffer (Tris-HCl 5 mM, pH 7.4) and
incubated at 23°C for 20 min prior to final centrifugation at 10,000 
g at 4°C. The pellet was resuspended in assay buffer (55 ml/gram of
original tissue) and frozen rapidly at 80°C until use.
On the day of assay the membranes were thawed and displace-
ment studies were carried out using an incubation volume of 1 ml
containing 0.4–0.5 mg membrane protein, 5 mM Tris-HCl buffer
(pH 7.4), 10 nM [3H]-MK801 and increasing concentrations of
MK801 and nefopam (from 1010 to 105 M and from 107 to 102 M
respectively).
The mixture was incubated for 45 min at 23°C and then subjected
to rapid filtration through Whatman GF/B filters, which were
washed immediately with two 5 ml portions of ice-cold assay buffer
in a Millipore filter system. The time required for the complete
filtration and washing procedure was less than 10 seconds. Radio-
activity retained on the filters was determined by using a conven-
tional liquid scintillation counter (Packard, Meriden, CT, USA).
Protein concentration were determined according to the method of
Lowry et al. (1951).
All experiments were carried out in duplicate.
Data presentation and analysis
For statistical analysis the one-way or the two-way analysis of vari-
ance (ANOVA) was used to identify overall treatment effects,
followed by the unpaired two-tailed Student’s t-test for selective
comparison of individual data groups. Only significances relevant
for the discussion of the data are indicated in each figure.
Materials
[3H]MK801 (22.5 Ci/mmol) was purchased from DuPont/NEN
(Boston, MA, USA). Unlabeled ()-10,11-dihydro-5-methyl-5H-
dibenzo-[a,d]-cyclohepten-5,10-imine hydrogen maleate (MK-801)
was obtained from RBI (Natick, MA, USA) as well as from Sigma.
Saxitoxin was a generous gift of Dr. V. Zitko of St. Andrews
Biological Station, N.B. (Canada). Veratridine, L-glutamate, and
orphenadrine were from Sigma.
Results
The exposure of cultured cerebellar neurons to gluta-
mate results within 30 min in swelling and darkening
of cell bodies and appearance of varicosities in neu-
rites (Novelli et al., 1988). These signs could be
completely prevented by the N-methyl-D-aspartate
(NMDA) receptor antagonist MK-801. Thus, this is a
convenient paradigm for testing the effectiveness of
drugs against the early onset of excitotoxicity, and
we used it for testing the potential anti-excitotoxic
properties of nefopam as compared to those of
orphenadrine. As reported in Table 1, orphenadrine
(100 µM) effectively prevented the appearance of
early excitotoxicity signs, while nefopam (100 µM) did
not.
Next we tested whether nefopam could be effective
in preventing the development of excitotoxicity in the
24 h following the exposure to glutamate. As shown in
Fig. 1, nefopam did not reduce glutamate toxicity. We
also tested the possibility that Nefopam may require
a longer incubation time before exposure to gluta-
mate for maximum effectiveness. However, neither
early sign of neurotoxicity nor neuronal survival after
24 h were ameliorated following pre-incubation with
nefopam for up to 3.5 h before expose to glutamate
(data not shown). Higher concentrations of nefopam
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(1 mM) were toxic to neurons after 24 h exposure
(data not shown).
In order to establish whether nefopam possess
any affinity for the phencyclidine binding site of the
NMDA receptor, where orphenadrine is known to
bind (Kornhuber et al., 1995), we tested the effec-
tiveness of nefopam in displacing MK-801 binding
from rat hippocampal membranes. As shown in Fig. 2,
100 µM nefopam did not significantly displaced MK-
801 binding to hippocampal membranes, whereas
approximately 1 mM nefopam was necessary to dis-
place MK-801 binding by 50%.
We then tested whether nefopam could have any
effect on glutamatergic neurotransmission by modu-
lating glutamate release. For this purpose, we induced
glutamate release from cerebellar neurons in culture
by depolarizing them with veratridine (Gallo et al.,
1982). Activation of voltage sensitive sodium channels
(VSSC) by veratridine (10 µM) results within 30 min
in swelling and darkening of cell bodies and appear-
ance of varicosities in neurites (Diaz-Trelles et al.,
2000). These signs are similar to those elicited by expo-
sure of cultures to toxic concentrations of exogenous
glutamate (Novelli et al., 1988), and they could be
completely prevented by the N-methyl-D-aspartate
(NMDA) receptor antagonist MK-801 (1 µM) (Diaz-
Trelles et al., 2000). Exposure of cultures to nefopam
(100 µM) for 5 min before veratridine stimulation
completely prevented the appearance of veratridine-
induced NMDA receptor-dependent excitotoxicity
(Table 1).
Exposures to veratridine for 24 h led to a significant
reduction in neuronal survival that occurred in the
presence of MK-801 (Diaz-Trelles et al., 2000). As
shown in Fig. 3, nefopam prevented neurodegenera-
tion following 24 h exposure to veratridine to the same
extent as the VSSC blocker saxitoxin (50 nM) (Terlau
et al., 1991).
In order to exclude that nefopam may protect
from veratridine–induced neurotoxicity by activating
GABA receptors, we pretreated cultures with
muscimol before the addition of veratridine. As
shown in Table 2, neither the early NMDA receptor-
dependent nor the later NMDA receptor-independent
phase of veratridine-induced neurotoxicity were re-
duced by the presence of muscimol.
Table 1. Effect of nefopam and orphenadrine on excitotoxicity
Toxicity signs at 30 min.
NONE MK-801 Orphenadrine Nefopam
NONE    
VTD    
GLU    
Cerebellar neurons in primary culture were exposed to the indicated
drugs. Nefopam, MK-801 and orphenadrine were added 5min. be-
fore other drugs. Drugs were used at the following concentration:
veratridine (VTD), 10µM; glutamate (GLU), 40µM; Nefopam,
100µM; orphenadrine, 100µM; MK-801, 2µM. The presence () or
the absence () of signs of early neurotoxicity such as darkening
and swelling of cell bodies were evaluated at 30 min. (n.d)– not done.
Fig. 1. Orphenadrine and nefopam effect on glutamate toxicity.
Neuronal cultures were exposed to the indicated drugs and neuronal
survival was determined 24 h later. MK-801 (1 µM), orphenadrine
(ORPH, 100 µM) and nefopam (NEF, 100 µM), were added 5 min
before glutamate (GLU, 40 µM). Values represent the mean  SD
from at least two independent experiments. * P  0.01 vs. GLU
Table 2. Muscimol does not reduce neither early nor late phases of
veratridine neurotoxicity
Toxicity signs Neuronal survival
at 30 min. at 24h (%)
NONE VTD NONE VTD
NONE   94  4 10  5a
MUSCIMOL   95  6 12  6a
NEFOPAM   96  5 92  8b
Cerebellar neurons in primary culture were exposed to the indicated
drugs. Nefopam, and Muscimol were added 5min. before other
drugs. Drugs were used at the following concentration: veratridine
(VTD), 10µM; Nefopam, 100µM; Muscimol, 100µM. The presence
() or the absence () of signs of early neurotoxicity such as dark-
ening and swelling of cell bodies were evaluated at 30min. Neuronal
survival was determined 24h later as indicated in the text. Values
represent the mean  SD (n  2–6).
a P  0.01 vs. NONE in the same line.
b P  0.01 vs VTD in the same column.
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Discussion
The chemical analogy of orphenadrine, a non competi-
tive antagonist at the NMDA receptor (Kornhuber et
al., 1995), with nefopam, suggest the possibility of a
similar action for the latter drug. Our results demon-
strate that unlike orphenadrine, nefopam was not
useful in preventing NMDA-receptor mediated
neurotoxicity following the direct exposure to gluta-
mate. When comparing nefopam to orphenadrine for
neuroprotection against glutamate toxicity, it should
be considered that: 1) approximately 1 mM nefopam
was required to inhibit by 50% MK-801 binding to rat
hippocampal membranes (Fig. 2), while no displace-
ment of Mk-801 binding was observed at the concen-
tration of nefopam used in neuronal cultures; 2)
approximately 20 µM orphenadrine was reported to
inhibit by 50% MK-801 binding to human prefrontal
cortex membranes (Kornhuber et al., 1995); 3) MK-
801 binding in the forebrain of human and rodents
possess a Kd of similar magnitude (Quarum et al.,
1990); 4) the Kd for MK-801 binding in the rat cerebel-
lum is approx. one order of magnitude lower than in
the forebrain (Reynolds and Palmer, 1991; Ebert et al.,
1991). Thus, it appears reasonable that the concentra-
tion of orphenadrine we used in this study may have
provided significant protection from excitotoxicity,
while nefopam did not.
On the other hand, our data indicate a novel effect
of nefopam on VSSC. The capability of depolarizing
stimuli such as veratridine to release glutamate from
cultured cerebellar neurons has been demonstrated
previously (Gallo et al., 1982), and the amount of
glutamate released is sufficient to activate NMDA
receptors, to stimulate cGMP synthesis (Fernández-
Sánchez et al., 1993), and to induce excitotoxicity
(Diaz-Trelles et al., 2000). Thus, our data provide
novel evidence suggesting that nefopam may modu-
late glutamatergic neurotransmission.
The early (30 min) MK-801-sensitive excitotoxic
component of veratridine toxicity was important in
determining the speed of the neurodegenerative pro-
cess, but it had a very minor contribution to the overall
toxicity by veratridine after 24 h (Diaz-Trelles et al.,
2000). This late, MK-801-independent toxicity, may be
attributed to the large influx of sodium through the
persistently activated VSSC and the activation of bio-
chemical pathways, such as oxygen radical formation,
leading to neuronal death (Fernández-Sánchez et al.,
2002).
Cultured cerebellar neurons express GABA recep-
tors (Gallo et al., 1984), and GABAergic neurons
account for approximately 3% of total neuronal
population in these cultures (Nicoletti et al., 1986).
Therefore, it is possible to speculate that nefopam
could mimic the action of GABA receptor agonists
and protect neurons by increasing GABAergic inhi-
bitory neurotransmission. However, neither the
NMDA receptor-mediated nor the NMDA receptor-
independent component of veratridine-induced toxic-
Fig. 3. Nefopam protects neurons from NMDA receptor-
independent component of veratridine toxicity. Neuronal cultures
were exposed to veratridine (VTD 10 µM) for 24 h. Nefopam
(NEF, 100 µM) or Saxitoxin (STX, 50 nM) were added 5 min prior
to VTD. Values represent the mean  SD from three independent
experiments (n  6). * P  0.01 vs.VTD
Fig. 2. Inhibition of [3H]MK-801 binding to rat hippocampal
membranes by unlabelled MK-801 and nefopam. The details of the
experimental procedure are reported in the methods. Values are
mean  SD of duplicate determinations from one representative
experiment that has been repeated with very similar results
Nefopam, an analogue of orphenadrine 35
ity, were reduced by the GABA receptor agonist
muscimol, rendering such possibility unlikely.
It is tempting to speculate that the actions on VSSC
we report may play a significant role in the analgesic
effects of nefopam. Several lines of evidence suggest
sodium channel inhibition to be a mechanism for
analgesia (Besson, 1999). The sodium channel blocker
carbamazepine has been shown to be effective in the
treatment of neuropathic pain (Rizzo, 1997; Harke et
al., 2001). Intrathecal administration of the sodium
channel blocker lamotrigine produced a spinal long-
lasting antihyperalgesic effect in short- and long-term
neuropathic models of hyperalgesia (Klamt, 1998).
Also, an inhibition of veratridine-induced sodium
influx has been found for antidepressants and neuro-
leptics used in chronic pain (Deffois et al., 1996). Con-
sidering that NMDA receptor activation appears to be
critical for the development and maintenance of the
centrally mediated events in the course of this neu-
ropathy (Kim et al., 1997; Kuwamata and Omote,
1996), our evidence that nefopam may modulate
depolarization-dependent glutamate release, is consis-
tent with nefopam capability to strongly reduce beha-
vioral and electrophysiological signs of the neuropathy
induced by ligature of the sciatic nerve (Biella et al.,
2002).
In conclusion, this study demonstrates the analgesic
compound nefopam hydrochloride to reduce neuronal
death following the activation of voltage-operated
sodium channels in cultured cerebellar neurons. This
novel action of nefopam may be of interest in reduc-
ing the excessive release of endogenous glutamate in-
volved in some neurological and neurodegenerative
disorders.
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